Results 111 to 120 of about 4,179 (208)

[<sup>18</sup>F]AlF-FAPI-74 PET/CT for preoperative assessment of the peritoneal cancer index and comparison with MRI-based, surgical and pathological assessment in colorectal cancer patients eligible for CRS-HIPEC: study protocol for a prospective observational proof-of-concept study. [PDF]

open access: yesBMJ Open
van den Bos M   +18 more
europepmc   +1 more source

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. [PDF]

open access: yesJ Nucl Med
Jeanjean P   +14 more
europepmc   +1 more source

Formal Security Analysis of the OpenID FAPI 2.0 Family of Protocols: Accompanying a Standardization Process [PDF]

open access: yes
FAPI 2.0 is a suite of Web protocols developed by the OpenID Foundation\u27s FAPI Working Group (FAPI WG) for third-party data sharing and digital identity in high-risk environments.
Pedram Hosseyni   +2 more
core  

PET Imaging in Pulmonary Hypertension. [PDF]

open access: yesArterioscler Thromb Vasc Biol
van Leent MMT   +6 more
europepmc   +1 more source

The Role of <sup>68</sup>Ga-FAPi PET/CT in Staging and Restaging of Breast Cancer Subtypes with Limited <sup>18</sup>F-FDG Uptake. [PDF]

open access: yesMol Imaging Radionucl Ther
Beydağı G   +7 more
europepmc   +1 more source

Advancing cancer imaging: The role of FAPI and Its clinical potential

open access: yes
Fibroblast Activation Protein (FAP) in cancer Types FAPI tracers used in clinical application and tracer used for labelling FAPI related article published FAPI vs FDG Challenges with FAPI based imaging What ahead in future Where is the New Zealand now in
Vyas, Madhusudan
core  

Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells. [PDF]

open access: yesOncoimmunology
Boutier H   +15 more
europepmc   +1 more source

FAP-Inhibitor Homodimers with Engineered Linker-Spacer Units: Toward Optimized Radiopharmaceuticals. [PDF]

open access: yesACS Omega
Kumar N   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy